Niagen Bioscience, Inc. (NAGE) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Niagen Bioscience, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Medicinal Chemicals & Botanical Products
High 3.02 at 12:45 pm ET, low 2.99 at 9:30 am ET.
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
the bull case· 2
6
disclosed supplier and customer ties in SEC filings
sec filingsedgar138
managers reporting a position in thirteen f filings
13fJun 30 '26the bear case· 4
12.50%
of revenue from the largest disclosed customer A.S. Watson Group
10-Kfiled Mar 4 '2614 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26−4.40%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '265 of 6
recent reports where the move came in under the options implied range
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 6 companies Niagen Bioscience, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2833, Medicinal Chemicals & Botanical Products, from each company's own filings. Largest first.
137 managers report a position worth $102.4M between them, and 20 of them hold 80% of it.
tall tick = annual report · 1 on record
NAGE (Niagen Bioscience, Inc.) has 3 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.